2001 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
Background: Neoadjuvant anthracycline- and taxane-based chemotherapy is frequently administered in breast cancer. Pathological complete response (pCR) rates vary according to clinical disease stage and biology of breast cancer. The critical role of angiogenesis in the progression of breast cancer, together with significantly improved efficacy...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
IMPORTANCE Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function is controversial owing to both the lack of data on long-term ovarian function and pregnancies and the safety concerns about the potential negative interactions between endocrine...
Uploaded on: April 14, 2023 -
2013 (v1)Publication
Estrogen synthesis suppression induced by aromatase inhibitors in breast cancer (BC) patients may be affected by single nucleotide polymorphisms (SNPs) of the gene encoding aromatase enzyme, CYP19A1. We assessed the association between plasma estrone sulfate (ES), letrozole treatment, and four SNPs of CYP19A1 gene (rs10046 C > T, rs4646 G > T,...
Uploaded on: March 27, 2023 -
2011 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2015 (v1)Publication
Background Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefit of increased density of dosing. We aimed to address these questions in terms of improvements in disease-free survival. Methods In...
Uploaded on: March 27, 2023